Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc.

In a report released today, Edward Tenthoff from Piper Sandler assigned a Buy rating to Karyopharm Therapeutics, with a price target of $8.00. Tent...

Piper Sandler Releases a Buy Rating on Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics ( ($KPTI) ) has provided an update. On March 24, 2026, Karyopharm announced a $30 million private placement with RA Capital...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KPTI	$7.26	+0.62%	338.48K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KPTI	$7.26	+0.6%	338.48K
3
4
5
6

KPTI

KPTI

No Data Available

Get Karyopharm Therapeutics Inc. Data in Excel

Get Karyopharm Therapeutics Inc. Data in Excel